Lymphoma, T-Cell, Cutaneous
"Lymphoma, T-Cell, Cutaneous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.
| Descriptor ID |
D016410
|
| MeSH Number(s) |
C04.557.386.480.750.800 C15.604.515.569.480.750.800 C20.683.515.761.480.750.800
|
| Concept/Terms |
Lymphoma, T-Cell, Cutaneous- Lymphoma, T-Cell, Cutaneous
- T-Cell Lymphoma, Cutaneous
- T Cell Lymphoma, Cutaneous
- Cutaneous T-Cell Lymphoma
- Cutaneous T Cell Lymphoma
- Cutaneous T-Cell Lymphomas
- Lymphoma, Cutaneous T-Cell
- Lymphomas, Cutaneous T-Cell
- T-Cell Lymphomas, Cutaneous
- Lymphoma, T Cell, Cutaneous
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, T-Cell, Cutaneous".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, T-Cell [C04.557.386.480.750]
- Lymphoma, T-Cell, Cutaneous [C04.557.386.480.750.800]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, T-Cell [C15.604.515.569.480.750]
- Lymphoma, T-Cell, Cutaneous [C15.604.515.569.480.750.800]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, T-Cell [C20.683.515.761.480.750]
- Lymphoma, T-Cell, Cutaneous [C20.683.515.761.480.750.800]
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, T-Cell, Cutaneous".
This graph shows the total number of publications written about "Lymphoma, T-Cell, Cutaneous" by people in this website by year, and whether "Lymphoma, T-Cell, Cutaneous" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma, T-Cell, Cutaneous" by people in Profiles.
-
Breaking Down the Barriers for Patients With Cutaneous T-Cell Lymphoma: Current Controversies and Challenges for Radiation Oncologists in 2024. Semin Radiat Oncol. 2025 Jan; 35(1):110-125.
-
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. Lancet Oncol. 2025 Jan; 26(1):110-122.
-
Small-Molecule CCR4 Antagonists in Cutaneous T-cell Lymphoma. Cancer Res Commun. 2024 10 01; 4(10):2756-2765.
-
Radiotherapy in the treatment of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder. Int J Dermatol. 2025 Feb; 64(2):385-389.
-
Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):e21-e32.e4.
-
New JAK3-INSL3 Fusion Transcript-An Oncogenic Event in Cutaneous T-Cell Lymphoma. Cells. 2023 09 29; 12(19).
-
Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory s?zary syndrome. Invest New Drugs. 2023 04; 41(2):350-355.
-
Cutaneous T-Cell Lymphoma: Current and Emerging Therapies. Oncology (Williston Park). 2023 02 24; 37(2):55-62.
-
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2022 09 01; 158(9):1031-1039.
-
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood. 2022 08 04; 140(5):419-437.